202 related articles for article (PubMed ID: 35410028)
21. Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy.
Emet S; Dadashov M; Sonsoz MR; Cakir MO; Yilmaz M; Elitok A; Bilge AK; Mercanoglu F; Oncul A; Adalet K; Onur I
Am J Med Sci; 2018 Dec; 356(6):537-543. PubMed ID: 30342718
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3: a modifiable risk factor in heart failure.
de Boer RA; van der Velde AR; Mueller C; van Veldhuisen DJ; Anker SD; Peacock WF; Adams KF; Maisel A
Cardiovasc Drugs Ther; 2014 Jun; 28(3):237-46. PubMed ID: 24789662
[TBL] [Abstract][Full Text] [Related]
23. Biomarker-based risk prediction in the community.
AbouEzzeddine OF; McKie PM; Scott CG; Rodeheffer RJ; Chen HH; Michael Felker G; Jaffe AS; Burnett JC; Redfield MM
Eur J Heart Fail; 2016 Nov; 18(11):1342-1350. PubMed ID: 27813304
[TBL] [Abstract][Full Text] [Related]
24. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases.
Gocer H; Günday M; Ünal M
Clin Ter; 2019; 170(4):e267-e271. PubMed ID: 31304514
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.
van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; de Boer RA; Asselbergs FW; Wajon EMCJ; Orsel JG; Boersma E; Hillege HL; Akkerhuis KM;
J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29187387
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.
Vergaro G; Del Franco A; Giannoni A; Prontera C; Ripoli A; Barison A; Masci PG; Aquaro GD; Cohen Solal A; Padeletti L; Passino C; Emdin M
Int J Cardiol; 2015 Apr; 184():96-100. PubMed ID: 25697876
[TBL] [Abstract][Full Text] [Related]
27. Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology.
Hara A; Niwa M; Kanayama T; Noguchi K; Niwa A; Matsuo M; Kuroda T; Hatano Y; Okada H; Tomita H
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899694
[TBL] [Abstract][Full Text] [Related]
28. The role of galectin-3 in heart failure and cardiovascular disease.
Zhong X; Qian X; Chen G; Song X
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study.
Wang H; Chen Q; Li Y; Jing X; Liang T; Yang J
Acta Cardiol; 2017 Apr; 72(2):188-195. PubMed ID: 28597803
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.
Parker DM; Everett AD; Stabler ME; Vricella L; Jacobs ML; Jacobs JP; Thiessen-Philbrook H; Parikh CR; Brown JR
J Card Surg; 2019 May; 34(5):329-336. PubMed ID: 30942505
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients.
Wang N; Dang M; Zhang W; Lei Y; Liu Z
Scand J Immunol; 2020 May; 91(5):e12826. PubMed ID: 31514240
[TBL] [Abstract][Full Text] [Related]
32. Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients.
Behnes M; Bertsch T; Weiss C; Ahmad-Nejad P; Akin I; Fastner C; El-Battrawy I; Lang S; Neumaier M; Borggrefe M; Hoffmann U
Int J Cardiol; 2016 Jan; 203():398-406. PubMed ID: 26539964
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure.
Miller WL; Saenger AK; Grill DE; Slusser JP; Bayes-Genis A; Jaffe AS
J Card Fail; 2016 Apr; 22(4):249-55. PubMed ID: 26277907
[TBL] [Abstract][Full Text] [Related]
34. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
Meijers WC; van der Velde AR; de Boer RA
Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
[TBL] [Abstract][Full Text] [Related]
35. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL
Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680
[TBL] [Abstract][Full Text] [Related]
36. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
Carrasco-Sánchez FJ; Páez-Rubio MI
Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
[TBL] [Abstract][Full Text] [Related]
37. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
[TBL] [Abstract][Full Text] [Related]
39. [The Prognostic Role of Biomarkers in Patients With Chronic Heart Failure].
Kurlianskaya EK; Mrochek AG; Denisevich TL; Kaliadka MG; Russkich II
Kardiologiia; 2020 Feb; 60(1):16-22. PubMed ID: 32245350
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive review of the prognostic value of galectin-3 in heart failure.
Coburn E; Frishman W
Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
